United Therapeutics (UTHR) Common Equity (2009 - 2026)

United Therapeutics has disclosed Common Equity across 18 years of filings, most recently posting $6.4 billion for Q2 2026.

• In Q2 2026, Common Equity fell 10.78% year-over-year to $6.4 billion; the TTM figure through Jun 2026 stood at $6.4 billion (down 10.78% YoY), while the FY2025 annual figure was $7.1 billion, up 10.12% from the prior year.
• Common Equity came in at $6.4 billion for Q2 2026 at United Therapeutics, up from $5.9 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $7.2 billion in Q2 2025 to a low of $4.2 billion in Q1 2022.
• Average Common Equity over 5 years is $5.8 billion, with a median of $5.8 billion recorded in 2023.
• Year-over-year, Common Equity gained 27.52% in 2025 and decreased 13.31% in 2026.
• Over 5 years, Common Equity stood at $4.8 billion in 2022, then gained by 24.77% to $6.0 billion in 2023, then increased by 7.67% to $6.4 billion in 2024, then advanced by 10.12% to $7.1 billion in 2025, then declined by 9.81% to $6.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $6.4 billion in Q2 2026, $5.9 billion in Q1 2026, and $7.1 billion in Q4 2025.